{"filing":{"accession_number":"0001193125-26-337962","cik":"0000943819","ticker":"RSMDF","company_name":"RESMED INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d158732d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/943819/000119312526337962/d158732d8k.htm"},"events":[{"id":25602,"run_id":23238,"accession_number":"0001193125-26-337962","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Resmed disclosed quarterly and fiscal year 2026 financial results for the period ended June 30, 2026, reporting revenue growth of 9% to $1.5 billion in Q4 and 10% to $5.7 billion for FY2026, with detailed financial statements and EPS metrics included in the earnings announcement.","company_name":"RESMED INC","ticker":"RSMDF","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26482,"accession_number":"0001193125-26-337962","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Resmed's quarterly and fiscal year 2026 financial results. The Item 2.02 disclosure explicitly states \"The press release describes the results of our operations for the quarter and fiscal year ended June 30, 2026,\" and the attached Exhibit 99.1 contains the full earnings announcement with detailed financial statements, revenue growth of 9% to $1.5 billion in Q4 and 10% to $5.7 billion for FY2026, and EPS metrics. This is a material disclosure affecting investor assessment of the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:23.237100+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25603,"run_id":23238,"accession_number":"0001193125-26-337962","anchor_item_number":"8.01","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Resmed announced a quarterly cash dividend of $0.66 per share, representing a 10% increase from the previous dividend, with a record date of August 20, 2026 and payment date of September 24, 2026.","company_name":"RESMED INC","ticker":"RSMDF","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26483,"accession_number":"0001193125-26-337962","item_number":"8.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure announces a quarterly cash dividend of $0.66 per share, representing a 10% increase over the previous dividend, with record date August 20, 2026 and payment date September 24, 2026. This is a clear dividend declaration affecting all common stockholders and CDI holders. The supplemental earnings release confirms this is part of Resmed's capital return program, making it material to investors assessing shareholder returns.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:23.237100+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26482,"accession_number":"0001193125-26-337962","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Resmed's quarterly and fiscal year 2026 financial results. The Item 2.02 disclosure explicitly states \"The press release describes the results of our operations for the quarter and fiscal year ended June 30, 2026,\" and the attached Exhibit 99.1 contains the full earnings announcement with detailed financial statements, revenue growth of 9% to $1.5 billion in Q4 and 10% to $5.7 billion for FY2026, and EPS metrics. This is a material disclosure affecting investor assessment of the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:23.237100+00:00","company_name":"RESMED INC","ticker":"RSMDF","filing_date":"2026-08-06"},{"id":26483,"accession_number":"0001193125-26-337962","item_number":"8.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure announces a quarterly cash dividend of $0.66 per share, representing a 10% increase over the previous dividend, with record date August 20, 2026 and payment date September 24, 2026. This is a clear dividend declaration affecting all common stockholders and CDI holders. The supplemental earnings release confirms this is part of Resmed's capital return program, making it material to investors assessing shareholder returns.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:23.237100+00:00","company_name":"RESMED INC","ticker":"RSMDF","filing_date":"2026-08-06"}]}